Ongoing links and partnerships

OUR PARTNER PROJECTS

REMEDi4ALL is an EU-funded research initiative to drive forward the repurposing of medicines in Europe. The platform has the potential to bring down times and costs of drug development by focusing on already approved, discontinued, shelved or investigational therapeutics. The REMEDi4ALL consortium brings together a unique combination of expertise to address the complexities of drug repurposing. Under the leadership of EATRIS, the European infrastructure for translational medicine, 24 organisations in the fields of clinical and translational research, clinical operations, patient engagement and education, regulatory framework, funding, governance, Health Technology Assessment (HTA) and pricing and reimbursement will closely collaborate to make drug repurposing mainstream.

LEARN MORE

CODING (COmputational Drug RepurposING) aims at training authentic European leaders in the use of in silico approaches for drug repurposing, by integrating a variety of established and ad-hoc newly developed computational strategies. CODING fosters a multidisciplinary environment, in which different expertise and vantage points will be joined together, at the interface between biology, chemistry and computer science. With a significant contribution from pharma companies, the collaborative team of experts will design a solid conceptual framework to develop, analyse, compare, aggregate and validate computational pipelines tailored to DR. The developed tools will be validated and applied prospectively in the context of different diseases, including, but not limited to, neurodegenerative diseases, cancer, SARS-CoV-2, inflammation, and others.

BioXplor‘s platform prioritises mechanisms, targets, known compounds and patient-level data to accelerate a degree of confidence in strategic decisions, for early-stage drug discovery, clinical trial conduct, and patient population stratification. The Platform is powered by proprietary algorithms that analyse over 35 million scientific publications (full text and abstracts), clinical trials, and genomics data, supported by 15,000 databases and custom ontologies, creating over 250 million interactome relationships.

LEARN MORE

REPO-TRIAL is a €5.5M EU funded platform for developing a computerized (in silico) approach to optimise the efficacy and precision of drug repurposing trials. It aims to improve the efficacy and precision of drug repurposing by redefining diseases entirely mechanistically, as opposed to merely descriptive definitions by symptom or organ. To reach this goal, REPO-TRIAL will exploit the existing wealth of medical big data and use advanced algorithms and cutting edge in silico modelling.

LEARN MORE